Strategic Reports Multiplexed Diagnostics 2008 (Published June 2008 by Select Biosciences) Multiplexed diagnostics are the wild west of medicine. Technology is established, regulation is limited and the number of new biomarkers exploding. First-movers are grabbing biomarker territories, combining independent measurements for efficiency and mining molecules for multivariate panels. All the while demand is high for improving diagnoses and predicting responses to treatment. The challenges, however, are uncertain reimbursement, unclear business models and ever-intensifying competition. On balance, though, the market is prosperous. It is estimated to be more than $1.5 billion in 2007 and is projected to grow to more than $6 billion by 2013. Successful navigation of this difficult terrain requires a detailed understanding of the market. This report explains the unmet needs, trends, regulations, competition, technologies and business strategies. The 260-page report includes a survey of more than 200 respondents, a detailed database of more than 135 commercial multiplexed diagnostics and a quantitative market model. To learn more, please contact us and/or please download the Table of Contents, Sample Pages or the Survey . The report comes with one hour of consulting (in the form of a conference call) with the lead author, Steven Bodovitz. To purchase a report, please visit Select Biosciences. Guide to Business Plan Writing, 3rd edition (Published December 2007 by D&MD) A business is a complex enterprise. To succeed, you need a plan. To convince others that you will succeed, you need to communicate your plan. When you develop your plan, you need to incorporate all of the complexity. You need to match your technology (or concept) with your market, your intellectual property, your team, your competitive advantage(s), your research and development, your production, your distribution, your marketing and your strategy. You need to ensure that the complexity translates into profitability and return on investment. Once you have your plan in place, you need to communicate it. You need to convince the right people to support you by joining your team, contributing to your venture, partnering with your company and/or investing in your vision. You need to translate your model for an interconnected enterprise into a linear document. You need to convince and inspire a skeptical audience with a short attention span and specific expectations. This guide will take you through the entire process, from planning your business to writing your plan. Because each business is different, with unique strengths and weaknesses, and opportunities and challenges, this guide will advise and direct, but leave you the freedom to express your vision as you see it. Next-Generation Immunoassays: A Market and Technical Analysis of Research Applications (Published November 2007 by BioPerspectives and Bachmann Consulting) The immunoassay assay is undergoing a major makeover. New amplification methods offer the promise to peer deeper into the proteome; new detection methods offer the promise to see clearer; new multiplexing to look faster and more efficiently; and new content to observe farther. These new technologies are addressing significant unmet needs in sensitivity, accuracy, speed, cost and breadth. This report details the opportunities and challenges in a market valued at more than $1.1 billion in 2003 and projected to grow to more than $2.2 billion in 2012. The report is based on surveys of researchers and thorough evaluations of more than 70 technologies encompassing novel antibody generation, real-time detection, new amplification methods and multiplexed antibody arrays. The financial projections are based on a 3 by 5 market matrix model encompassing instruments, antibodies and other reagents and consumables across ELISAs, Western blots, immunoprecipitations, antibody arrays and novel antibody characterization methods. To learn more, please contact us and/or please download the Table of Contents or the Sample Pages . The report is available for purchase by check or wire transfer, and the price of US$3,950 includes a site license, an electronic file and an hour of consultation (via conference call) with one of the authors. Point of Care Diagnostics Market in the US: Opportunities and Challenges (Published August 2006 by BioPerspectives) Diagnosing at the point of care offers many advantages: increased patient empowerment, improved clinical outcomes, and fewer days at the hospital. As a result, physicians are ordering more point of care tests and companies are racing to meet growing demand. Their efforts are made easier by improved knowledge of diseases and drug responses at the molecular level and improved technologies that enable simpler, more self-contained testing. These trends, according to a new report from BioPerspectives, are expected to drive double-digit growth over the next five years. According to this new report, the market is expected to grow from $5.5 billion in 2005 to as much as $7.5 billion in 2010. But this opportunity is not without challenges. Point of care diagnostics is a highly competitive and challenging marketplace, with more than 50 companies and 40 types of tests, not to mention regulatory guidelines, reimbursement challenges, and information technology infrastructure needs. Moreover, point of care testing is inherently more expensive than central laboratory-based testing on a per test basis, resulting in intense price pressure. Success in this market depends on a detailed understanding of the trends, the unmet needs, the technologies, and the prices. This report from BioPerspectives is the ideal tool for planning for success. The comprehensive analysis of the US market is based on (1) a proprietary comprehensive database of tests, (2) discussions with clinicians, (3) detailed assessments of current and emerging technologies, and (4) CDC, FDA, and professional organizational guidelines and publications. Twenty-one figures, 32 tables, and profiles of 57 companies present the information in a simple and readily accessible manner. This report is the go-to tool for those wishing to enter and those wishing to stay current in this dynamic market. To learn more, please contact us and/or please download the Table of Contents or the Sample Pages . The report is available for purchase by check or wire transfer, and the price of US$3,650 includes a site license, an electronic file, and an hour of free consulting (via conference call) with one of the authors. Market Opportunities and Challenges for Antibody Arrays and Beads (Written by BioPerspectives and Published by D&MD in October 2005) More than 100 companies are developing or have developed antibody array and/or bead platforms. The competition is fierce, but the progress in the field has been slow. The problem has been a disconnect between the capabilities of the available technologies and the demands of the market place. This analysis goes right to the demands of the marketplace, identifying and analyzing current and future practices, unmet needs, and opportunities and challenges. It provides key information for companies to optimize their strategies to take advantage of the large opportunities and avoid the major pitfalls. For more information click here. Protein Biochips: Parallelized Screening for High-Output Biology (Published August 2004 by BioPerspectives) The protein biochip industry is shedding hype and demonstrating real value. The grandiose visions of technologies to study the entire human proteome are giving way to pragmatic divide-and-conquer approaches. This transition is driving the projected growth in the market from $122 million in 2002 to more than $500 million in 2008, according to this new report written by an international team of experts. The comprehensive, 267-page report has unparalleled analysis and coverage of the protein biochip market, including both planar and bead arrays. The report features a detailed discussion of the key drivers and a 3 X 2 X 2 X 2 hierarchical market model. In addition, the report features detailed evaluations of the technologies and business strategies of 60 companies. Furthermore, to enable readers to take full advantage of the expertise of the authors, the report comes with one free hour of consulting. To learn more about our report, read the press release, or download the Table of Contents, or sample pages or contact us for more information. The report is available for purchase by check or wire transfer, and the price of US$999.00 includes a site license, an electronic file and an hour of free consulting (via conference call) with one of the authors. RNAi 2004 (Published January 2004 by Select Biosciences) RNAi is the hotest technology in biotechnology. It has the potential to revolutionize biology research and drug target discovery by evolving genomics from inferring correlation to determining causation. It has the potential to rapidly and cost-effectively determine the function of putative drug targets as well as serve as a broad-based platform for developing targeted therapeutics. This report provides a detailed market analysis based on a thorough investigation of technologies, applications, intellectual property, unmet needs and trends. The report includes interviews with experts, evaluations of leading companies, qualitative and quantitative market models across multiple segments of the RNAi value chain, and strategic recommendations for capitalizing on specific opportunities. Contact Select Biosciences for more information. Secondary Screening 2003 (Published October 2003 by Select Biosciences) 90% of compounds fail in drug development because of four reasons. 41% fail because of poor ADME; 31% because of insufficient efficacy; 22% because of toxicity; and only 6% because of market and/or commercialization complications. The earlier in the development process that an inadequate compound can be removed, the less time and money wasted, usually on the order of five to ten years and hundreds of millions of dollars. The market opportunity to re-screen hits to validate efficacy after primary high-throughput screening is approximately $190 million worldwide and expected to grow to more than $250 million by 2005. The market opportunities for toxicology and ADME currently total approximately $3 billion, most of which is spent on animal studies. The market for in vitro toxicology testing, the segment within secondary screening, is approximately $200 million and expected to grow to more than $300 million by 2005. The market for in vitro ADME testing represents a conversation opportunity and is forcasted to remain relatively stable. The growth within all three of these segments is driven by a diverse set of new technologies, including high-content screening platforms and cellular models of toxicology and metabolism. Most of these technologies are distributed across more than 40 companies, but a significant amount of industry consolidation is expected over the next two years to integrate instruments, reagents, and informatics/data management solutions. Navigating this dynamic competitive landscape and emerging market requires business intelligence. For more information on this report contact Select Biosciences. Proteomics 2003 (Published July 2003 by Select Biosciences) Proteomics technologies have dramatically accelerated the study of proteins, resulting in the discovery of thousands of potential biomarkers and drug targets. Further advances, primarily in mass spectrometry, are expected to increase the rate of discovery. The proteomics market grew from $1.1 billion in 2001 to almost $1.4 billion in 2002 and, based on first quarter numbers, the growth rate is continuing in 2003. But the success is creating a bottleneck. High-throughput and/or high-output technologies are used to discover potential biomarkers and drug targets, but the validation methods are low-throughput and low-output. For proteomics to continue its current growth rate, the industry needs new methods and technologies to speed validation. Fortunately, multiple emerging technologies are poised to meet this need. Contact Select Biosciences for more information about this report. Protein Biochips 2003 (Published April 2003) The protein biochip market is underserved, despite growing from $70 million in 2001 to $100 million in 2002. The market is projected to grow to more than $400 million in 2007, a compound annual growth rate of more than 35%. This report presents a detailed market model and thorough analysis of the technologies and business strategies of nearly 40 leading protein biochip companies. Contact us for more information. Protein Biochips: On the Threshold of Success (Published March 2002) With at least 25 companies either selling protein biochips today or preparing to enter the market within the next two years, sales in this industry are poised for enormous growth. BioInsights presents a thorough analysis of both the technology and business strategies of 25 leading protein biochip makers. BioInsights predicts that sales of protein biochips will top $700 million in 2006, a ten-fold increase from sales of $76 million in 2001. Here is the press release. You may also print out some sample pages from the report as well as a sample company profile. Contact us for more information. Functional Proteomics: Short-Cuts to Drug Discovery (Published June 2001) Innovative, diverse technologies are typical of the multitude of companies entering the functional proteomics field. They are all hoping they have found the clever, new angle that will dramatically expedite the drug discovery process. If they are right, the market is in for an exciting future. For more information about this report, read the press release, or view our map of functional proteomics. Or, contact us for more information. Protein Chips: The Race for High-Throughput Protein Analysis (Published December 2000) Protein chips have the potential to meet the demand for high-throughput protein analysis spawned by the explosion of data on gene sequences and expression patterns. A spate of new companies and new technologies, if successful, will propel the protein chip market forward at a rapid growth rate. To learn more about our report, read the press release, or click on report summary, or report structure. Alternatively, contact us for more information. Combinatorial Biology: New Products and Processes from Genetic Diversity (Published August 2000) Directed evolution — the acceleration and optimization of the most successful method for developing biological products — has enormous potential to improve and expand industrial enzymes, therapeutic proteins, small molecule drugs, and tools for target discovery and validation.  Combinatorial biology companies have already signed numerous deals with chemical and pharmaceutical companies, but their biggest opportunities for growth will come from milestone and royalty payments as well as the development of their own products. To learn more about our report, read the press release, our summary or contact us for more information. Angiogenesis Inhibitors: A Detailed Analysis of Emerging Compounds (Published March 2000) Angiogenesis inhibitors are an exciting new class of therapeutics — they target pathologic growth of blood vessels, they generally have mild or no toxicity, and they have the potential to treat a range of diseases. Initially, use of this new class of drugs will focus on cancer treatment but future applications will include treatments for psoriasis, arthritis, and ocular disease. For a report summary click here or read our press release.  Alternatively, contact us for more information. Biochips: From Hype to Reality (Published December 1999) After a period of hype and unrealistic expectations, Biochips — DNA chips, lab chips and protein chips — are moving into real-world applications. Biochips have established themselves as a required research tool for expression profiling, and have the opportunity for similar success in diagnostics, pharmacogenomics, high-throughput screening, and toxicology screening. To learn more about our report, read the press release or click on report summary,  or report structure. You may also contact us for more information.